Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats.

@article{GaryBobo2007RimonabantRO,
  title={Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats.},
  author={Magali Gary-Bobo and Ghizlane Elachouri and Jean François Gallas and Philip Janiak and Pietro Marini and Christine Ravinet-Trillou and Mich{\`e}le Chabbert and No{\"e}l Cruccioli and Christian Pfersdorff and Claude Roque and Mich{\`e}le Arnone and Tiziano Croci and Philippe Soubri{\'e} and Florence Oury-Donat and Jean Pierre Maffrand and Bernard Scatton and Frederic Lacheretz and G{\'e}rard Le Fur and Jean Marc Herbert and Mohammed Bensaid},
  journal={Hepatology},
  year={2007},
  volume={46 1},
  pages={122-9}
}
This study investigated the effects of rimonabant (SR141716), an antagonist of the cannabinoid receptor type 1 (CB1), on obesity-associated hepatic steatosis and related features of metabolic syndrome: inflammation (elevated plasma levels of tumor necrosis factor alpha [TNFalpha]), dyslipidemia, and reduced plasma levels of adiponectin. We report that oral treatment of obese (fa/fa) rats with rimonabant (30 mg/kg) daily for 8 weeks abolished hepatic steatosis. This treatment reduced… CONTINUE READING
Highly Influential
This paper has highly influenced 11 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS
138 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 138 extracted citations

Similar Papers

Loading similar papers…